Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia

Open Access

Peer-reviewed

Research Article

Silvia Catellani,

Affiliation Clinical Oncohaematology, Department of Internal Medicine, University of Genoa, Genoa, Italy
⨯
Ivana Pierri,

Affiliation Clinical Oncohaematology, Department of Internal Medicine, University of Genoa, Genoa, Italy
⨯
Marco Gobbi,

Affiliation Clinical Oncohaematology, Department of Internal Medicine, University of Genoa, Genoa, Italy
⨯
Alessandro Poggi ,

* E-mail: alessandro.poggi@istge.it (AP); zocchi.maria@hsr.it (MRZ)

Affiliation Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research, Genoa, Italy
⨯
Maria Raffaella Zocchi

* E-mail: alessandro.poggi@istge.it (AP); zocchi.maria@hsr.it (MRZ)

Affiliation Division of Immunology, Transplants and Infectious Diseases, Scientific Institute San Raffaele, Milan, Italy
⨯

Reader Comments (0)

B cells
Is the Subject Area "B cells" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Lymphocytes
Is the Subject Area "Lymphocytes" applicable to this article?

Thanks for your feedback.
Leukemia
Is the Subject Area "Leukemia" applicable to this article?

Thanks for your feedback.
Enzyme-linked immunoassays
Is the Subject Area "Enzyme-linked immunoassays" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cytokines
Is the Subject Area "Cytokines" applicable to this article?

Thanks for your feedback.
Cytokine therapy
Is the Subject Area "Cytokine therapy" applicable to this article?

Thanks for your feedback.